On-column thiol protection strategy to control charge and stability of ThiomAb
Antibody Therapeutics · 29.06.2026 · 9 (3) · 312-322
DOI: 10.1093/abt/tbag023 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antibody Therapeutics, online erschienen am 11.06.2026. Verfasst von Kai Ni und 7 weiteren Autor:innen. Beteiligte Einrichtung: Biotherapeutics Process Development, Takeda Development Center Americas, 200 Shire Way, Lexington, MA 02421, United States. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Cysteine-engineered monoclonal antibodies (mAbs), or ThiomAb, enable site-specific conjugation and form the basis of several next-generation antibody-drug conjugates (ADCs). However, the presence of intentionally unpaired cysteine residues introduces reactive free thiols that pose challenges for manufacturing consistency, including variable capping by cysteine/glutathione or uncapped free thiol during cell culture. This increases the charge heterogeneity of protein and may compromise stability due to increased risk of oxidation, disulfide scrambling, or aggregation.
Methods
To address these risks, we developed an on-column capping strategy, in which the antibody is immobilized on chromatography resin during the capture step and subjected to selective thiol masking under optimized redox conditions. This in-process approach allows for early and efficient stabilization of engineered thiol sites prior to polishing and formulation. High-throughput condition screening and analytical techniques—including mass spectrometry and charge variant profiling—were employed to fine-tune buffer conditions and understand on-column redox chemistry.
Results
The optimized thiol protection conditions substantially reduce the population of free thiols, resulting in more consistent charge profiles and improved stability during downstream processing and storage.
Conclusion
This strategy offers a scalable and platform-adaptable solution for enhancing the manufacturability and alternative control strategy of ThiomAb intermediates used in site-specific ADC processes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Biotherapeutics Process Development, Takeda Development Center Americas, 200 Shire Way, Lexington, MA 02421, United States.
- Analytical Development, Takeda Development Center Americas, 200 Shire Way, Lexington, MA 02421, United States.
ORCID-Profile: Kai Ni, Leo Lei Wang
Zitieren
APA
Ni, K., Wang, L. L., Shupe, A., Cooney, T., Dai, J., Barton, C., Parks, G., & Alves, C. (2026). On-column thiol protection strategy to control charge and stability of ThiomAb. Antibody Therapeutics, 9(3), 312-322. https://doi.org/10.1093/abt/tbag023
Vancouver
Ni K, Wang LL, Shupe A, Cooney T, Dai J, Barton C, et al. On-column thiol protection strategy to control charge and stability of ThiomAb. Antibody Therapeutics. 2026;9(3):312-322. doi:10.1093/abt/tbag023
BibTeX
@article{Ni2026,
author = {Ni, Kai and Wang, Leo Lei and Shupe, Alan and Cooney, Timothy and Dai, Joshua and Barton, Christopher and Parks, George and Alves, Christina},
title = {On-column thiol protection strategy to control charge and stability of ThiomAb},
journal = {Antibody Therapeutics},
year = {2026},
volume = {9},
number = {3},
pages = {312--322},
doi = {10.1093/abt/tbag023}
}
EUVIMED